1-11 of 11
Jan H. M. Schellens
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT154: Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumors

Ulrik Lassen, Morten Mau-Sørensen, Ulla Hald Buhl, Mogens W. Madsen, Eva Balslev, Dick Pluim, Jan H. M. Schellens, Steen Knudsen, Peter B. Jensen
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT154.
https://doi.org/10.1158/1538-7445.AM2016-CT154
Published: 15 July 2016
View article titled, Abstract CT154: Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumors
Journal Articles

Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer

Jan H. M. Schellens, Robin van Geel, Johanna C. Bendell, Anna Spreafico, Martin Schuler, Takayuki Yoshino, Jean-Pierre Delord, Yasuhide Yamada, Martijn P. Lolkema, Jason E. Faris, Ferry A. L. M. Eskens, Sunil Sharma, Rona Yaeger, Heinz-Josef Lenz, Zev A. Wainberg, Emin Avsar, Arkendu Chatterjee, Savina Jaeger, Tim Demuth, Josep Tabernero
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): CT136.
https://doi.org/10.1158/1538-7445.AM2015-CT136
Published: 01 August 2015
View article titled, Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer
Journal Articles

Abstract SF1-2: Improving access to innovative anticancer medicines: a clinicians viewpoint

Jan H. M. Schellens
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): SF1-2.
https://doi.org/10.1158/1538-7445.SABCS14-SF1-2
Published: 01 May 2015
View article titled, Abstract SF1-2: Improving access to innovative anticancer medicines: a clinicians viewpoint
Journal Articles

ABC transporters and cancer treatment

Jan H. M. Schellens
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 1476–1477.
Published: 01 May 2005
View article titled, ABC transporters and cancer treatment
Journal Articles

Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions

Pauline Breedveld, Noam Zelcer, Dick Pluim, Özgür Sönmezer, Matthijs M. Tibben, Jos H. Beijnen, Alfred H. Schinkel, Olaf van Tellingen, Piet Borst, Jan H. M. Schellens
Journal: Cancer Research
Cancer Res (2004) 64 (16): 5804–5811.
https://doi.org/10.1158/0008-5472.CAN-03-4062
Published: 16 August 2004
View article titled, Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: <subtitle>Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions</subtitle>
Open the PDF for Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: <subtitle>Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions</subtitle> in another window
Journal Articles

The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Restricts Exposure to the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine

Antonius E. van Herwaarden, Johan W. Jonker, Els Wagenaar, Remco F. Brinkhuis, Jan H. M. Schellens, Jos H. Beijnen, Alfred H. Schinkel
Journal: Cancer Research
Cancer Res (2003) 63 (19): 6447–6452.
Published: 14 October 2003
View article titled, The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Restricts Exposure to the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
Open the PDF for The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Restricts Exposure to the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in another window
Journal Articles

Differential Effects of the Breast Cancer Resistance Protein on the Cellular Accumulation and Cytotoxicity of 9-Aminocamptothecin and 9-Nitrocamptothecin

Rajeev Rajendra, Murugesan K. Gounder, Ahamed Saleem, Jan H. M. Schellens, Douglas D. Ross, Susan E. Bates, Patrick Sinko, Eric H. Rubin
Journal: Cancer Research
Cancer Res (2003) 63 (12): 3228–3233.
Published: 15 June 2003
View article titled, Differential Effects of the Breast Cancer Resistance Protein on the Cellular Accumulation and Cytotoxicity of 9-Aminocamptothecin and 9-Nitrocamptothecin
Open the PDF for Differential Effects of the Breast Cancer Resistance Protein on the Cellular Accumulation and Cytotoxicity of 9-Aminocamptothecin and 9-Nitrocamptothecin in another window
Journal Articles

Low Systemic Exposure of Oral Docetaxel in Mice Resulting from Extensive First-Pass Metabolism Is Boosted by Ritonavir

Heleen A. Bardelmeijer, Mariët Ouwehand, Tessa Buckle, Maarten T. Huisman, Jan H. M. Schellens, Jos H. Beijnen, Olaf van Tellingen
Journal: Cancer Research
Cancer Res (2002) 62 (21): 6158–6164.
Published: 01 November 2002
View article titled, Low Systemic Exposure of Oral Docetaxel in Mice Resulting from Extensive First-Pass Metabolism Is Boosted by Ritonavir
Open the PDF for Low Systemic Exposure of Oral Docetaxel in Mice Resulting from Extensive First-Pass Metabolism Is Boosted by Ritonavir in another window
Journal Articles

Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in Normal Human Tissues

Marc Maliepaard, George L. Scheffer, Ian F. Faneyte, Margôt A. van Gastelen, Adriana C. L. M. Pijnenborg, Alfred H. Schinkel, Marc J. van de Vijver, Rik J. Scheper, Jan H. M. Schellens
Journal: Cancer Research
Cancer Res (2001) 61 (8): 3458–3464.
Published: 15 April 2001
View article titled, Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in Normal Human Tissues
Open the PDF for Subcellular Localization and Distribution of the Breast Cancer Resistance Protein Transporter in Normal Human Tissues in another window
Journal Articles

Breast Cancer Resistance Protein Is Localized at the Plasma Membrane in Mitoxantrone- and Topotecan-resistant Cell Lines

George L. Scheffer, Marc Maliepaard, Adriana C. L. M. Pijnenborg, Margôt A. van Gastelen, Mariska C. de Jong, Anouk B. Schroeijers, Dorina M. van der Kolk, John D. Allen, Douglas D. Ross, Paul van der Valk, William S. Dalton, Jan H. M. Schellens, Rik J. Scheper
Journal: Cancer Research
Cancer Res (2000) 60 (10): 2589–2593.
Published: 15 May 2000
View article titled, Breast Cancer Resistance Protein Is Localized at the Plasma Membrane in Mitoxantrone- and Topotecan-resistant Cell Lines
Open the PDF for Breast Cancer Resistance Protein Is Localized at the Plasma Membrane in Mitoxantrone- and Topotecan-resistant Cell Lines in another window
Journal Articles

Overexpression of the BCRP/MXR/ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line

Marc Maliepaard, Margôt A. van Gastelen, Laurina A. de Jong, Dick Pluim, Robert C. A. M. van Waardenburg, Marjan C. Ruevekamp-Helmers, Ben G. J. Floot, Jan H. M. Schellens
Journal: Cancer Research
Cancer Res (1999) 59 (18): 4559–4563.
Published: 15 September 1999
View article titled, Overexpression of the <em>BCRP/MXR/ABCP</em> Gene in a Topotecan-selected Ovarian Tumor Cell Line
Open the PDF for Overexpression of the <em>BCRP/MXR/ABCP</em> Gene in a Topotecan-selected Ovarian Tumor Cell Line in another window